Home
Overview
Programs
Technology
Publications Business Developement Press Contact
 
5/26/09 KineMed Enters into Collaboration with Bristol-Myers Squibb
1/29/09 KineMed Describes Innovative Approach to Discover and Develop Drugs to Treat Fibrosis and Identifies Potential Drug for Lung and Liver Fibrosis
1/6/09 KineMed Awarded Michael J. Fox Foundation Funding to Validate Translational Biomarker of Microtubule Function in Parkinson's Disease
8/14/08 Dr. Robert Stein, MD, PhD, Named CEO of KineMed
1/1/08 Repositioning Idle Drugs via Systematic Serendipity; Systems-based Approaches for Boosting Stalled Drugs
  more...

2007 Whole-Body Glycolysis Measured by the Deuterated-Glucose Disposal Test Correlates Highly With Insulin Resistance In Vivo Diabetes Care.
2005 Emerging applications of kinetic Biomarkers in preclinical and clinical drug development
  more...


KineMed uniquely employs both pathway-based drug discovery and translational medicine-enabled drug development.

KineMed's pathway-based discovery is based upon its unique ability to identify drugs with true therapeutic effect that effectively modulate the kinetics of key metabolic pathways. By screening compounds against these dynamic targets of key metabolic pathways that are the etiological basis for important diseases, KineMed can rapidly demonstrate a drug's on-mechanism activity in both animals and patients.

Translational medicine is the science of developing more predictive transitions from preclinical animal efficacy to human efficacy. With its proprietary ability to rapidly demonstrate whether a compound can effectively modulate the same metabolic pathway in both animals and man, KineMed is ideally positioned to de-risk the clinical development of new drug therapies. By measuring the real-time activity of drugs against their targeted metabolic pathways, KineMed can rapidly and easily identify therapeutic efficacy and dose response in First-in-Man studies.

KineMed works both with pharmaceutical companies and on its own developmental projects to speed new drugs to clinical use.

  • In partnership with leading pharma companies or in our own development projects, we use these proven technologies to expedite the discovery of drugs that modulate biological pathways to mediate disease.
  • For our lead programs, we are using both our pathway -based development technology to identify active drug candidates and our translational medicine capabilities to confirm the activity and dose-response in First-in-man studies.